Clinical trial · Interventional
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium
NCT00397488CI-TRIAL-00020639completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with progressive metastatic transitional cell cancer of the urothelium.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Transitional Cell Cancer of the Renal Pelvis and Ureter | — | UNRESOLVED | — |
| Urethral Cancer | Malignant Urethral Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sunitinib malate | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sunitinib
- description
- This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
- interventionNames
- Drug: sunitinib malate
Primary outcomes (1)
- measure
- Overall Objective Response
- timeFrame
- 2 years
- description
- Response rate as measured by RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed transitional cell carcinoma of the urothelium, including 1 of the following sites:
* Bladder
* Urethra
* Ureter
* Renal pelvis
* Progressive metastatic disease
* Progressive disease defined as new or progressive lesions on cross-sectional imaging
* Progressed despite prior treatment with cytotoxic chemotherapy
* Measurable disease
* Previously treated disease, as defined by the following:
* Received treatment with 1-4 cytotoxic agents
* Prior therapy must have included ≥ 1 of the following:
* Cisplatin
* Carboplatin
* Paclitaxel
* Docetaxel
* Gemcitabine hydrochloride
* Prior cytotoxic agents in the perioperative or metastatic setting allowed and may have been administered sequentially (e.g., first-line treatment followed by second-line treatment at time of progression) or all as part of a single regimen
* No symptomatic CNS metastases
PATIENT CHARACTERISTICS:
* Karnofsky performance status 60-100%
* Absolute neutrophil count ≥ 1,000/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 8.0 g/dL
* Bilirubin ≤ 1.5 mg/dL (unless Gilbert's disease is present)
* AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver function abnormalities are due to underlying malignancy)
* Creatinine ≤ 2.0 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* None of the following within the past 6 months:
* Myocardial infarction
* Severe or unstable angina
* Coronary or peripheral artery bypass graft
* Symptomatic congestive heart failure
* Cerebrovascular accident or transient ischemic attack
* Pulmonary embolism
* No ongoing cardiac dysrhythmias ≥ grade 2
* No prolonged QTc interval on baseline ECG
* No uncontrolled hypertension, defined as blood pressure \> 150/100 mm Hg despite optimal medical therapy
* No preexisting thyroid abnormality (i.e., thyroid function tests that cannot be maintained in the normal range with medication)
* No known HIV- or AIDS-related illness or other active infection
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* At least 4 weeks since prior radiotherapy or chemotherapy
* At least 4 weeks since prior major surgery
* No other concurrent investigational drugs
* No concurrent participation in another clinical trial (supportive care trials or non-treatment trials \[e.g., quality of life\] allowed)
* No concurrent therapeutic doses of warfarin (low-dose warfarin ≤ 2 mg once daily for thromboembolic prophylaxis allowed)References
Publications (0)
Data not yet available
No reference posted for this study.